HK Stock Market Move | LAENA-B (02105) surged more than 11%, star weight-loss drug to be launched soon. Research on subcutaneous injection of LAE102 for stage I obesity has started.

LAEKNA-B (02105) rose more than 11% in early trading, up 8.49% as of writing, at 11.5 Hong Kong dollars, with a turnover of 36.2716 million Hong Kong dollars. On the news front, on November 17, biopharmaceutical company Novo Nordisk announced that the global first and currently only long-acting GLP-1RA weekly formulation, Novo Ying (semaglutide injection for long-term weight management), was officially launched in China. It is reported that Novo Ying can achieve an average weight reduction of about 17%, and its weight loss effect can last for at least two years. It was reported that Laike Pharmaceuticals announced in mid-October that it had started subcutaneous injection queues in its Phase I single-dose escalation study (SAD study). The Phase I clinical trial aims to evaluate the safety, tolerability, and pharmacokinetics of LAE102 injection, with the hope of completing the single-dose escalation study by the end of 2024. LAE102 is a monoclonal antibody developed independently targeting ActRIIA, a receptor that plays an important role in muscle regeneration and fat metabolism. The group is committed to bringing this precision treatment to overweight and obese patients who need new treatment options to achieve high-quality weight control.